John Kollins

John Kollins has more than 30 years of biopharmaceutical industry experience and currently serves as President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company he cofounded to develop STS101 (dihydroergotamine [DHE] nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraines.